SCHEMBL4871956

SCHEMBL4871956

O=C(Nc1cccc(OCc2ccccc2)c1)N1CCCCc2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.67
MAPK1 P28482 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
LMNA P02545 5/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
TP53 P04637 3/20 0.58
POLB P06746 2/20 0.56
ATM Q13315 1/20 0.56
NPC1 O15118 1/20 0.55
PKM P14618 1/20 0.55
NFKB1 P19838 1/20 0.55
RAB9A P51151 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
THRB P10828 1/20 0.55
FAAH O00519 1/20 0.53
MAPT P10636 1/20 0.53
HTT P42858 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4862251 0.88 TP53 (0.67) LMNATP53POLBNPC1PKM
SCHEMBL4863830 0.87 TP53 (0.66) LMNATP53POLBNPC1PKM
SCHEMBL4870653 0.87 PDK1 (0.61) LMNATP53POLBNPC1PKM
SCHEMBL4554972 0.85 MAPT (0.69) ALDH1A1MAPK1L3MBTL1LMNAMEN1
SCHEMBL4869342 0.84 PDK1 (0.60) LMNATP53POLBTHRBFAAH
SCHEMBL4865966 0.84 TP53 (0.57) LMNATP53POLBTHRBFAAH
SCHEMBL4869678 0.84 TP53 (0.62) ALDH1A1MAPK1L3MBTL1LMNAMEN1
SCHEMBL4871110 0.84 TP53 (0.59) LMNATP53POLBTHRBMAPT
SCHEMBL4863054 0.83 TP53 (0.65) ALDH1A1MAPK1L3MBTL1LMNAMEN1
SCHEMBL4863168 0.83 MEN1 (0.71) ALDH1A1MAPK1L3MBTL1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 ALDH1A1 3990/4885MAPK1 2006/4885L3MBTL1 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.